Combined BRAF (dabrafenib) and MEK inhibition (trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor

Journal of Clinical Oncology

Volumn 32, Issue 33, 2014, Pages 3697-3704

  Johnson, Douglas B ^a   Flaherty, Keith T ^c   Weber, Jeffrey S ^d   Infante, Jeffrey R ^b   Kim, Kevin B ^e   Kefford, Richard F ^f   Hamid, Omid ^h   Schuchter, Lynn ^j   Cebon, Jonathan ^g   Sharfman, William H ^l   McWilliams, Robert R ^m   Sznol, Mario ⁿ   Lawrence, Donald P ^c   Gibney, Geoffrey T ^d   Burris, Howard A ^b   Falchook, Gerald S ^e   Algazi, Alain ⁱ   Lewis, Karl ^o   Long, Georgina V ^f   Patel, Kiran ^p   Ibrahim, Nageatte ^k   Sun, Peng ^k   Little, Shonda ^k   Cunningham, Elizabeth ^k   Sosman, Jeffrey A ^a   Daud, Adil ⁱ   Gonzalez, Rene ^o   more..

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF SYDNEY   (Australia)

^g AUSTIN HEALTH   (Australia)

^h Angeles Clinic and Research Institute   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k GLAXOSMITHKLINE   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

^m MAYO CLINIC   (United States)

ⁿ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^o UNIVERSITY OF COLORADO   (United States)

^p Incyte ^*  (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPYRETIC AGENT; CORTICOSTEROID; DABRAFENIB; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; IMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXIME; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; ASYMPTOMATIC DISEASE; BACKACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CENTRAL SEROUS RETINOPATHY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HYPERKERATOSIS; HYPERTENSION; HYPONATREMIA; HYPOTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RETINA VEIN OCCLUSION; TREATMENT DURATION; TUMOR BLEEDING; UROSEPSIS; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; MALE; MELANOMA; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; OXIMES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDONES; PYRIMIDINONES;

EID: 84911922237     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.3535     Document Type: Article

References (31)

1. Curtin JA, Fridlyand J, Kageshita T, et al: Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-2147, 2005
2. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
3. Lovly CM, Dahlman KB, Fohn LE, et al: Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS One 7:e35309, 2012
4. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
5. Flaherty KT, Robert C, Hersey P, et al: Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114, 2012
6. Hauschild A, Grob JJ, Demidov LV, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365, 2012
7. Sosman JA, Kim KB, Schuchter L, et al: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714, 2012
8. Su F, Viros A, Milagre C, et al: RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215, 2012
9. Callahan MK, Rampal R, Harding JJ, et al: Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 367:2316-2321, 2012
10. Andrews MC, Behren A, Chionh F, et al: BRAF inhibitor - driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. J Clin Oncol 31:e448-e451, 2013
11. Shi H, Hugo W, Kong X, et al: Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 4:80-93, 2014
12. Van Allen EM, Wagle N, Sucker A, et al: The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4:94-109, 2014
13. Rizos H, Menzies AM, Pupo GM, et al: BRAF inhibitor resistance mechanisms in metastatic melanoma: Spectrum and clinical impact. Clin Cancer Res 20:1965-1977, 2014
14. Nazarian R, Shi H, Wang Q, et al: Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977, 2010
15. Wagle N, Emery C, Berger MF, et al: Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096, 2011
16. Trunzer K, Pavlick AC, Schuchter L, et al: Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol 31:1767-1774, 2013
17. Poulikakos PI, Persaud Y, Janakiraman M, et al: RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-390, 2011
18. Shi H, Moriceau G, Kong X, et al: Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724, 2012
19. Montagut C, Sharma SV, Shioda T, et al: Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68:4853-4861, 2008
20. Johannessen CM, Boehm JS, Kim SY, et al: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972, 2010
21. Villanueva J, Vultur A, Lee JT, et al: Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695, 2010
22. Shi H, Hong A, Kong X, et al: A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov 4:69-79, 2014
23. Haq R, Shoag J, Andreu-Perez P, et al: Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23:302-315, 2013
24. Wilson TR, Fridlyand J, Yan Y, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487:505-509, 2012
25. Straussman R, Morikawa T, Shee K, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487:500-504, 2012
26. Paraiso KH, Fedorenko, IV, Cantini LP, et al: Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 102:1724-1730, 2010
27. Flaherty KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703, 2012
28. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
29. Wagle N, Van Allen EM, Treacy DJ, et al: MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov 4:61-68, 2014
30. Villanueva J, Infante JR, Krepler C, et al: Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 4:1090-1099, 2013
31. Long GV, Stroyakovsky DL, Gogas H, et al: COMBI-d: A randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma. J Clin Oncol 32:574s, 2014 (suppl 15s; abstr 9011)